Axsome Therapeutics (AXSM) Accumulated Expenses (2021 - 2026)
Axsome Therapeutics' Accumulated Expenses history spans 6 years, with the latest figure at $43000.0 for Q1 2026.
- On a quarterly basis, Accumulated Expenses fell 99.96% to $43000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $43000.0, a 99.96% decrease, with the full-year FY2025 number at $150.2 million, up 941.14% from a year prior.
- Accumulated Expenses hit $43000.0 in Q1 2026 for Axsome Therapeutics, down from $150.2 million in the prior quarter.
- Over the last five years, Accumulated Expenses for AXSM hit a ceiling of $150.2 million in Q4 2025 and a floor of $43000.0 in Q1 2026.
- Historically, Accumulated Expenses has averaged $22.5 million across 5 years, with a median of $4.5 million in 2024.
- Biggest five-year swings in Accumulated Expenses: skyrocketed 5672.63% in 2025 and later plummeted 99.96% in 2026.
- Tracing AXSM's Accumulated Expenses over 5 years: stood at $875000.0 in 2022, then skyrocketed by 643.2% to $6.5 million in 2023, then surged by 121.91% to $14.4 million in 2024, then surged by 941.14% to $150.2 million in 2025, then tumbled by 99.97% to $43000.0 in 2026.
- Business Quant data shows Accumulated Expenses for AXSM at $43000.0 in Q1 2026, $150.2 million in Q4 2025, and $7.0 million in Q3 2025.